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SP1 and p65 expression increase the effect
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Abstract
Background: Lung cancer is the most common cause of cancer-related deaths worldwide. Natural phytochemicals
from traditional medicinal plants such as solamargine have been shown to have anticancer properties. The
prostaglandin E2 receptor EP4 is highly expressed in human cancer, however, the functional role of EP4 in the
occurrence and progression of non small cell lung cancer (NSCLC) remained to be elucidated.
Methods: Cell viability was measured by MTT assays. Western blot was performed to measure the phosphorylation
and protein expression of PI3-K downstream effector Akt, transcription factors SP1, p65, and EP4. Quantitative real-
time PCR (qRT-PCR) was used to examine the mRNA levels of EP4 gene. Exogenous expression of SP1, p65, and EP4
genes was carried out by transient transfection assays. EP4 promoter activity was measured by Dual Luciferase
Reporter Kit.
Results: We showed that solamargine inhibited the growth of lung cancer cells. Mechanistically, we found that
solamargine decreased the phosphorylation of Akt, the protein, mRNA expression, and promoter activity of EP4.
Moreover, solamargine inhibited protein expression of SP1 and NF-κB subunit p65, all of which were abrogated in
cells transfected with exogenous expressed Akt. Intriguingly, exogenous expressed SP1 overcame the effect of
solamargine on inhibition of p65 protein expression, and EP4 protein expression and promoter activity. Finally,
exogenous expressed EP4 feedback reversed the effect of solamargine on phosphorylation of Akt and cell
growth inhibition.
Conclusion: Our results show that solamargine inhibits the growth of human lung cancer cells through inactivation
of Akt signaling, followed by reduction of SP1 and p65 protein expression. This results in the inhibition of EP4 gene
expression. The cross-talk between SP1 and p65, and the positive feedback regulatory loop of PI3-K/Akt signaling by
EP4 contribute to the overall responses of solamargine in this process. This study unveils a novel mechanism by which
solamargine inhibits growth of human lung cancer cells.
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Background
Lung cancer is the most common cancer and the leading
cause of cancer mortality worldwide for both men and
women [1]. Most patients present with incurable ad-
vanced or metastatic disease with poor 5-year survival
rate. Among them, more than 80 % of lung cancers are
non-small cell lung carcinoma (NSCLC) with adenocar-
cinoma as the most prevalent subtype [1]. The choice of
treatment for patients with advanced disease remains
dilemma and challenge, which dependent on the histo-
logical types, tumor characteristics, stages, co-morbidities
and prior therapies history. Inspire of the advance in un-
derstanding the molecular mechanism and treatment op-
tions, the poor patient survival still remain no changes
and the caused debilitating symptoms seriously affect the
quality of life of patients. Therefore, searching for more
effective alternative treatment strategies in order to
strengthen the therapeutic efficacy with negligible side ef-
fects is urgently needed.
Natural compounds, known as phytochemicals, ob-
tained from traditional medicinal plants have gained
more attention in the prevention and intervention of hu-
man illness including cancers [2]. solamargine (SM), the
typical metabolites of solanum lycocarpum fruit glycoal-
kaloid extract from traditional herbal medicine, demon-
strated not only anti-viral, anti-inflammatory but also
antiproliferative activity against the several types of hu-
man cancers including lung [3–7]. Report showed that
SM induced apoptosis and inhibited growth of hepatoma
SMMC-7721 cells through activation and induction ex-
pression of caspase-3 [8]. Early study found that com-
bination of low concentrations of SM with low-toxic
topoisomerase II inhibitor epirubicin synergistically ac-
celerated apoptotic cell death through up-regulation of
Fas expression and down-regulated the expression of
human epidermalgrowth factor receptor-2 (HER2) and
topoisomerase II alpha (TOP2A) in NSCLC A549 and
H441 cells [9] However, the detailed mechanisms and po-
tential therapeutic benefices by which this agent in con-
trolling the growth of human lung cancer cells have not
been well determined.
As a central to multiple signaling pathways, the
phosphatidylinositol-3-kinase (PI3-K)/protein kinase B
(Akt) has been shown to play an important role in a
wide variety of fundamental cellular processes, such as
proliferation, migration, apoptosis, metabolic homeosta-
sis, hypoxia, and recently immune-regulation. Aberrant
regulation of the PI3-K/Akt signaling axis is considered
as a primary causative node in major diseases including
cancer. It is therefore not surprising that this signaling
pathway is frequently dysregulated in cancers, making
the Akt important therapeutic target [10–13]. Activa-
tion of this pathway can be the result of mutations or
amplification of PI3-K/Akt itself, which is frequently
observed in multiple cancer types, such as NSCLC [14].
On the contrary, blockade of PI3K/Akt and other signal-
ing pathways have been involved in the anticancer activ-
ities in several cancer types including lung [13, 15–17].
One report showed that the combination of BGT226, a
novel PI3K/ mammalian target of rapamycin (mTOR)
dual inhibitor, and gefitinib, one of epidermal growth
factor receptor (EGF-R) tyrosine kinase inhibitors (TKIs),
had synergistically inhibitory effects in growth of NSCLC
cells through inhibition of PI3K/Akt/mTOR signaling
pathways [18].
The E-prostanoid receptor 4 (EP4) is one of four re-
ceptor subtypes for prostaglandin E2 (PGE2), the key
lipid mediators produced from arachidonic acid. It be-
longs to the family of G protein-coupled receptors and
plays an important role in various cellular processes,
such as inflammatory, angiogenesis, cancer growth, and
progression [19]. A possible explanation for the diverse
biological functions of EP4 might be the multiple signal-
ing pathways switched on upon activation and increased
expression of EP4 gene. A large body of evidence dem-
onstrated that activation and/or high expression of EP4
have been shown in several malignancies and associated
with growth and progression [19–23]. However, the
functional significance of EP4 expression in lung cancer
occurrence and progression remains to be elucidated.
In this study, we explored the potential mechanism by
which solamargine inhibits growth of human lung can-
cer cells.
Methods
Cell culture and chemicals
The human cancer cancer lines A549 and H1299 were
obtained from the (Sun Yat-sen Memorial Hospital, Sun
Yat-sen University) and the Chinese Academy of Sci-
ences Cell Bank of Type Culture Collection (Shanghai,
China). All cell lines have been tested and authenticated
for absence of Mycoplasma, genotypes, drug response,
and morphology in the Laboratory since 2012. Cells
were grown in RPMI 1640 medium (obtained from
GIBCO, Life Technologies, Grand Island, NY, USA) with
supplemented 10 % fetal bovine serum. Lipofectamine
3000 reagent was purchased from Invitrogen (Shanghai,
China). The polyclonal antibody against EP4 was ob-
tained from Abcam (Cambridge, MA, USA). The anti-
bodies against SP1, total Akt and the phosphor-form
(Ser473) were purchased from Cell Signaling Technology
Inc (Beverly, MA, USA). Other chemicals unless indi-
cated were obtained from Sigma-Aldrich (St. Louis, MO,
USA).
Cell viability assay
Cell viability was measured using the 3-(4, 5-dimethyl-
thiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT)
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assay [24]. In brief, NSCLC cells were harvested,
counted, and seeded in a 96-well microtitre plate. The
cells were treated with increasing concentrations of
solamargine for up to 72 h. After incubation, 20 μL
MTT solution (5 g/L) was added and incubated at 37 °C
for an additional 4 h. afterwards, the supernatant was
removed, followed by adding solvent dimethyl sulfoxide
(200 μL) to each well and oscillated for 8 min. Finally,
the absorbance of optical density at 490 nm was deter-
mined by ELISA reader (Perkin Elmer, Victor X5, USA).
Cell viability (%) was calculated as (absorbance of test
sample/absorbance of control) × 100 %.
Cell cycle analysis
This procedure was reported previously [24]. In brief,
NSCLC cells were cultured in 6-well plates at 1 × 105 cells/
well and treated with increased doses of solamargine for
24 h. Afterwards, the cells were harvested and resuspended
in 500 μL of cold PBS and cold ethanol (1.5 mL) for 2 h at
4 °C, followed by incubating with 0.1 % sodium citrate con-
taining propidium iodide (PI) 0.05 mg and 50 μg RNase
for 30 min. Finally, the cell cycle analysis was detected by
flow cytometry (FC500, Beckman Coulter, FL, USA), and
the proportion of cells within the G0/G1, S, and G2/M
phases of the cell cycle were analyzed using the MultiCycle
AV DNA Analysis software (Phoenix Flow Systems).
Transient transfection assay
The control, Akt, SP1, and EP4 overexpression vectors
(pCMV6-AC-Akt, pCMV6-AC-SP1, pCMV6-AC-EP4)
were obtained from OriGene Technologies, Inc. (Rockville,
MD, USA). The p65 overexpression construct (pCMV4-
p65) was obtained from the Addgene (Plasmid #21966)
[25]. Briefly, cells were seeded in 6-well dishes and grown
to 50–60 % confluence. For each well, 2 μg of control,
SP1, p65 and EP4 plasmid DNA constructs were trans-
fected into the cells using Lipofectamine 3000 reagent
(Invitrogen, Shanghai, China) for 30 h, followed by treating
with solamargine for an additional 24 or 48 h. In the sepa-
rated experiments, control and wild type EP4 promoter
constructs, a gift from Dr. Thomas Eling (NIEHS, USA),
which was reported previously [26], with or without
0.25 μg of the internal control pRL-CMV Renilla luciferase
reporter DNA (0.02 μg/well) were co-transfected into the
cells with Lipofectamine 3000 Transfection Reagent (Invi-
trogen, Shanghai, China). The preparation of cell extracts
and measurement of luciferase activities were determined
using the Dual-Luciferase Reporter kit (Promega, Beijing,
China). Firefly luciferase activity was normalized with
Renilla luciferase activity within each sample.
Western blot analysis
The detailed procedure was reported previously [2, 24].
Briefly, equal amounts of protein from whole cell lysates
were solubilized in 5 × SDS-sample buffers and separated
on 10-12 % SDS polyacrylamide gels. Membranes were in-
cubated with antibodies against EP4, p65, SP1, the phos-
phor and total Akt. The membranes were washed and
incubated with a secondary antibody raised against rabbit
IgG conjugated to horseradish peroxidase (Cell Signaling
Technology, Inc., Beverly, MA, USA). The membranes
were washed again and transferred to freshly made ECL
solution (Immobilon Western; Millpore, Billerica, MA,
USA), followed by observing the signals under the Mo-
lecular Imager ChemiDoc XRS Gel Imagine System (Bio-
Rad, Hercules, CA, USA) and documenting the results.
Quantitative real-time-PCR
A quantitative real-time-PCR (qRT-PCR) assay was per-
formed for the detection of EP4 transcripts. The primers
used in this study were designed as follows: EP4 forward
5’- TCGCGCAAGGAGCAGAAGGACAC -3’; reverse
5’- GACGGTGGCGAGAATGAGGAAGGA -3’ [26];
GAPDH forward 5’- AAGCCTGCCGGTGACTAAC -3’;
reverse 5’- GCGCCCAATACGACCAAATC -3’, which
was used as an internal control. First-strand cDNA was
synthesized from total RNA (2 μg) by reverse transcription
using oligo-dT primers and Superscript II reverse tran-
scriptase (Invitrogen, Grand Island, NY, USA) according
to the manufacturer’s instructions. qRT-PCR was per-
formed in a 20 μL mixture containing 2 μL of the cDNA
preparation, 10 μL 2X SYBR Green Premix ExTaq
(Takara), and 10 μM primer on an ABI 7500 Real-Time
PCR System (Applied Biosystems, Grand Island, NY,
USA). The PCR conditions were as follows: 10 min at
95 °C, followed by 40 cycles of 15 s at 95 °C, and
1 min at 60 °C. Each sample was tested in triplicate.
Threshold values were determined for each sample/primer
pair, the average and standard errors were calculated.
Statistical analysis
All experiments were repeated a minimum of three times.
All data were expressed as means ± SD. Differences be-
tween groups were assessed by one-way ANOVA and sig-
nificance of difference between particular treatment
groups was analyzed using Dunnett’s multiple comparison
tests (GraphPadPrism5.0 software, LaJolla, CA). Asterisks
shown in the figures indicate significant differences of ex-
perimental groups in comparison with the corresponding
control condition (P < 0.05, see figure legends).
Results
The effect of solamargine on growth of lung cancer cells
We first examined the effect of solamargine on lung
cancer cell growth. We showed that solamargine inhib-
ited the growth of H1299 and A549 lung cancer cells in
the dose-dependent manner with the most significant ef-
fect observed at 6 μM for up to 72 h (Fig. 1a). Note that
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low doses also showed significant response in H1299
and A549 lung cancer cells. The IC50 were 4.09 and
3.40 μM in H1299 and A549 cells, respectively. We also
performed the cell cycle experiment. Our results found
that, compared with the untreated control cells, sola-
margine significantly increased the proportion of cells
at G0/G1 phase, while the proportion of cells at S
phase were reduced at the 6 μM solamargine (Fig. 1b)
suggesting that solamargine induced cell cycle arrest
in G0/G1 phase in lung cancer cells.
Solamargine decreased phosphorylation of Akt
We then explored the signaling pathways that were in-
volved in the inhibitory response by solamargine in lung
cancer cells. We showed that solamargine decreased the
phosphorylation of Akt (ser473), a downstream effector
of PI3-K, in a time-dependent fashion with significant
reduction observed at 4-24 h in H1299 and A549 cells
(Fig. 2a-b).
Solamargine inhibited EP4 mRNA, protein and promoter
activity
Next, we examined the potential molecular targets by
solamargine. PGE2 receptor EP4 has been shown to
be associated with tumor growth and progression
[19–22]. We showed that solamargine reduced the
protein, mRNA expression, and promoter activity of
EP4 in H1299 and A549 cells suggesting solamargine
regulated EP4 at both transcriptional and translational
levels (Fig. 3a-c).
Fig. 1 The effect of solamargine on growth of lung cancer cells. a Lung cancer cell lines (H1299 and A549) were treated with increased
concentrations of solamargine for up to 72 h. Afterwards, the cell viability was determined using the MTT assay as described in the Materials and
Methods section. b A549 cells were treated with increased concentrations of solamargine for up to 48 h. Afterwards, the cells were collected and
processed for analysis of cell cycle distribution by flow cytometry after propidium iodide (PI) staining. The percentages of the cell population in
each phase (G0/G1, S and G2/M) were assessed by Multicycle AV DNA Analysis Software. Values are given as the mean ± SD from 3 independent
experiments performed in triplicate and expressed as a percentage of total cells. *indicates significant difference as compared to the untreated
group (P < 0.05). **Indicates significant difference from solamargine treated alone (P < 0.05)
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Solamargine inhibited SP1 protein through inactivation of
Akt; exogenous expressed SP1 abrogated the effect of
solamargine on EP4 expression
Moreover, we tested the role of transcription factor SP1
in this process. Previous studies found that EP4 pro-
moter contain SP1 binding sites and that SP1 regulated
the function and expression of EP4 [26]. Herein, we
showed that solamargine inhibited SP1 protein expres-
sion, which was abrogated in cells transfected with
exogenous expressed Akt in H1299 and A549 cells
(Fig. 4a-b). As expected, exogenous expression of SP1
overcame the effect of solamargine on EP4 protein ex-
pression and promoter activity in H1299 and A549 cells
(Fig. 4c-d). These results above suggested that SP1 is a
downstream of Akt but an upstream of EP4, and regu-
lated EP4 expression both at transcriptional and transla-
tional levels.
Solamargine inhibited p65 protein expression; exogenous
expressed p65 reversed solamargine-inhibited EP4
expression
We also characterized the additional transcription factor
NF-κB/p65 in this process. NF-κB signaling has been asso-
ciated with PGE2/EP4 pathway in other studies [27, 28]. To
this end, we showed that solamargine inhibited p65 protein
expression in H1299 and A549 cells (Fig. 5a), which was
not observed in the cells transfected with exogenous
expressed SP1 (Fig. 5b). Interestingly, overexpressed p65
reversed solamargine-inhibited EP4 protein expression
(Fig. 5c). Of note, exogenous expressed p65 had no ef-
fect on solamargine-inhibited SP1 protein expression in
H1299 and A549 cells (Fig. 5d) suggesting the down-
stream effector of SP1 but upstream signal of EP4 in this
process.
Overexpressed EP4 feedback antagonized the effect of
solamargine on phosphorylation of Akt and cell growth
inhibition
Finally, to further corroborate the critical role of EP4 in
this process, we transfected with exogenous expressed
EP4 plasmid into the cells. The results indicated
that overexpression of EP4 feedback antagonized
solamargine-inhibited phosphorylation of Akt (Fig. 6a)
and, more importantly, significantly blocked the effect
of solamargine on cell growth inhibition (Fig. 6b).
Note that overexpression of EP4 had no effect on
solamargine-reduced SP1 and p65 protein expression
(Fig. 6c-d). This result unveils a novel feedback regu-
latory loop and suggested that SP1 and p65 are both
upstream molecules of EP4.
Discussion
Lung cancer still remains a major threat to public health
worldwide, the incidence and motility rates have been in-
creased continuously. In spite of the advance in under-
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Fig. 2 Solamargine decreased phosphorylation of Akt. a-b H1299 and A549 cells were treated with solamargine (6 μM) in the indicated times,
and cell lysate was harvested and the expression of the phosphorylated and total protein of Akt was measured by Western blot. GAPDH was
used as loading control. Values in bar graphs were given as the mean ± SD from three independent experiments. *indicates significant difference
as compared to the untreated control group (P < 0.05)
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less progress has been made in improving quality of life
and survival in patients with advanced stage NSCLC
[1, 29]. Therefore, developing new adjunctive thera-
peutics to augment currently available treatment mo-
dalities without compromising therapeutic efficacy are
eagerly needed.
Solamargine, a steroidal alkaloid glycoside extracted
from the traditional Chinese herb Solanum incanum,
has been shown to inhibit growth and induce apoptosis
in various cancer types including lung through multiple
signaling pathways and mechanisms [4, 5, 30]. However,
the detailed molecular mechanism underlying inhibition
of proliferation of lung cancer cells still remain to be
elucidated. In this study, we demonstrated a significant
inhibition of lung cancer cell growth by solamargine.
The doses of solamargine examined in the current study
were similar or even lower than those reported by others
demonstrating substantial growth inhibition in several
cancer cell types [4, 30, 31].
In this study, we explored the potential mechanism by
which solamargine inhibited NSCLC cell growth. Our
results indicated a role of PI3-K/Akt signaling pathway
in mediating the effect of solamargine in inhibition of
lung cancer cell growth, suggesting that inactivation of
PI3-K/Akt increased the effect of solamargine in this
process. The activation of PI3-K/Akt axis implicates in
the regulation of other gene expression and cellular re-
sponses in various types of cancer including lung, there-
fore, approaches to harbor this signaling axis could be
valuable potential for treating cancers [32, 33]. Because
of the fact that less or no data have shown the links be-
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Fig. 3 Solamargine inhibited EP4 mRNA, protein and promoter activity. a H1299 and A549 cells were exposed to increased concentration of
solamargine for 24 h. Afterwards, the expression of EP4 proteins was detected by Western blot. b H1299 and A549 cells were treated with A549
and H1975 cells were exposed to solamargine (6 μM) for 24 h, followed by measuring the mRNA levels by qRT-PCR. c A549 and H1975 cells were
transfected with a wild type human EP4 promoter reporter construct ligated to luciferase reporter gene and internal control for 24 h, followed by
exposing to solamargine for an additional 24 h. Afterwards, the promoter activities of EP4 were determined using the Dual-Luciferase Reporter kit
(Promega), as described in the Materials and Methods section. Values in bar graphs were given as the mean ± SD from three independent experi-
ments performed in triplicate. *indicates significant difference as compared to the untreated group (P < 0.05)
Chen et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:154 Page 6 of 11
blockade of this signaling pathway could be part of the
anti-tumor mechanism of solamargine.
To further explore the potential mechanism under-
lying the aforementioned, we tested the role of EP4, one
of the PGE2 receptor, which was involved in prolifera-
tion, migration and invasion of cancer cells [19]. Our re-
sults indicated the critical role of EP4 involved in the
effect of solamargine on inhibition of lung cancer cell
growth, implying that EP4 could be a potential target in
the treatment of lung cancer. Recent studies showed that
inhibition of EP4 suppressed growth of several cancer
cell types emphasizing the important role of this prosta-
noid receptor [34, 35]. We believed that, as unfavorable
tumor-promoting role, EP4 could be a new target in
A549
A549
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Fig. 4 Solamargine inhibited SP1 protein expression through inactivation of Akt; exogenous expression of SP1 abrogated the effect of
solamargine on EP4 expression. a A549 and H1975 cells were treated with increased concentrations of solamargine for 24 h. Afterwards, the
expression of SP1 proteins was detected by Western blot. b A549 and H1975 cells were transfected with the control or expression construct of
Akt vectors for 24 h before exposing the cells to solamargine for an additional 24 h. Afterwards, the expression of Akt and SP1 proteins were
determined by Western blot, and was expressed as percentage of control in the mean ± SD of three separate experiments. GAPDH was used as
loading control. c A549 and H1975 cells were transfected with the control or expression constructs of SP1 for 24 h before exposing the cells to
solamargine for an additional 24 h. Afterwards, the expression of SP1 and EP4 proteins were determined by Western Blot, and was expressed as
percentage of control in the mean ± SD of three separate experiments. GAPDH was used as internal control. d A549 and H1975 cells were
transfected with the control or expression construct of SP1 and wild type EP4 promoter reporter construct ligated to luciferase reporter gene and
internal control for 24 h before exposing the cells to solamargine for an additional 24 h. Afterwards, the promoter activities were determined
using the Dual-Luciferase Reporter kit (Promega). Values in bar graphs were given as the mean ± SD from three independent experiments performed
in triplicate. *Indicates significant difference as compared to the untreated control group (P < 0.05). **Indicates significant difference from the
solamargine treated alone group (P < 0.01)
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mediating the inhibitory effect of solamargine in lung
cancer intervention.
Furthermore, we found a causative role of transcrip-
tion factor SP1 that involved in the effects of solamar-
gine on suppression of EP4 expression and lung cancer
cell proliferation. Our findings indicated that inhibition
of SP1 was required to enhance the effect of solamargine
on inhibition of EP4 receptor expression. The links of
EP4 and SP1 signaling have been shown in other studies
[22, 26]. Early study demonstrated that human EP4 gene
promoter contained SP1 DNA binding sites and regulated
EP4 expression [26]. Overexpression of SP1 has been
shown to overcome the inhibitory effect of curcumin on
EP4 promoter activity and protein expression in other
cancer cell types [22]. Thus, we reasoned that regulation
of SP1 played a crucial role in mediating solamargine-
inhibited EP4 expression in lung cancer cells.
We also observed the involvement of PI3-K/Akt sig-
naling pathway in the regulation of SP1 and EP4 in re-
sponse of solamargine-inhibited lung cancer cell growth.
The role of PI3-K/Akt signaling in the link of SP1 and
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Fig. 5 Solamargine inhibited p65 protein expression; exogenous expressed p65 reversed the solamargine-inhibited EP4 expression. a A549 and
H1975 cells were treated with increased concentration of solamargine for 24 h. Afterwards, the expression of p65 protein was detected by
Western blot. b A549 and H1975 cells were transfected with the control or expression constructs of SP1 for 24 h before exposing the cells to
solamargine for an additional 24 h. Afterwards, SP1 and p65 protein expression were determined by Western blot. c-d A549 and H1975 cells were
transfected with the control and p65 expression vectors for 24 h before exposing the cells to solamargine for an additional 24 h. Afterwards, the
p65, SP1 and EP4 protein were determined using Western blot. GAPDH was used as internal control. Values in bar graphs were given as the
mean ± SD from three independent experiments performed in triplicate. *Indicates significant difference as compared to the untreated control
group (P < 0.05). **Indicates significant difference from the solamargine treated alone group (P < 0.01)
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studies; activation of PI3-K/Akt could alter expression of
SP1 and EP4, and thereby influenced differentiation,
angiogenesis, metastasis, invasion in several different cell
systems [21, 36–38]. Interestingly, we observed a posi-
tive feedback regulatory axis of PI3-K/Akt by EP4. We
reasoned that this bidirectional feedback loop might also
implicate in the solamargine-inhibited lung cancer sig-
naling. The feedback regulation circuit of PI3-K/Akt
with other targets was reported in other studies demon-
strating common autocrine physiopathological phenom-
ena [39–41]. One study showed that NADPH oxidase 4
(NOX4) was highly expressed in NSCLC cells and there
existed a mutual positive regulatory loop between NOX4
and PI3-K/Akt signaling in NSCLC cells that contributed
to proliferation and progression [42]. Nevertheless, more
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Fig. 6 Overexpressed EP4 feedback antagonized the effect of solamargine on phosphorylation of Akt and cell growth inhibition. a A549 and
H1299 cells were transfected with control and EP4 overexpression vectors for 24 h before exposing the cells to solamargine (6 μM) for an
additional 2 h and 24 h. Afterwards, phosphorylation of Akt and EP4 protein expressions were determined by Western blot. b A549 and H1975
cells were transfected with control and EP4 overexpression vectors for 24 h before exposing the cells to solamargine (6 μM) for an additional
24 h. Afterwards, EP4 protein expressions and cell viability were determined using Western blot and MTT assays, respectively. Values in bar graphs
were given as the mean ± SD from three independent experiments performed in triplicate. *Indicates significant difference as compared to the
untreated control group (P < 0.05). **Indicates significant difference from the solamargine or plus control vector group (P < 0.01). c-d A549 and
H1299 cells were transfected with control (pCMV6) and EP4 overexpression vector for 24 h before exposing the cells to solamargine (6 μM) for an
additional 24 h. Afterwards, expressions of SP1, p65 and EP4 protein were determined by Western blot. e The diagram the shows that
solamargine inhibits the growth of lung cancer cells through inactivation of Akt, followed by reduction of SP1 and p65. This results in the
inhibition of expression of EP4 gene. The cross-talk between SP1 and p65, and the positive feedback regulatory loop of PI3-K/Akt signaling by
EP4 contribute to the overall responses of solamargine in this process
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mechanism such as the potential signaling pathways and
up- or downstream mediators that may be involved in
this unexplored regulatory circuit.
Moreover, our results illustrated the cross-talk be-
tween the SP1 and NF-κB/p65 that contributed to the
solamargine-reduced EP4 expression in lung cancer
cells. Previous studies found that EP4 promoter contain
several putative DNA binding sequences including SP1,
which could influence the function and expression of
EP4 [26]. Our findings indicated the upstream role of
SP1 in regulating the solamargine-reduced EP4 expres-
sion. Moreover, we also demonstrated the interaction be-
tween SP1 and p65, one subunit of NF-κB, suggesting
that inter-correlation of the transcription factors co-
operatively contributed to the inhibitory effects of sola-
margine on EP4 expression at both transcriptional and
translational levels. Accumulating evidence indicated
that deregulation and inter-collaboration of SP1 and NF-
κB/p65 expression was implicated in the several patho-
logical responses, such as growth and progression of
many cancer types, by affecting the expression of other
target genes [43–47] The critical roles of these transcrip-
tion factors in influencing the PGE2/EP4 signaling and
relevant connections-mediated functions were reported
in other studies [22, 28, 48, 49]. More experiments are re-
quired to determine if there is a physical binding between
SP1 and NF-κB/p65 that might regulate solamargine-
suppressed EP4 gene expression and subsequent cell
growth inhibition. In addition, whether this is a direct or
indirect interaction with other DNA sequences in the EP4
gene promoter remains to be elucidated. We believed that
understanding the complex oncogenic network is critical
for identifying therapeutic targets for lung cancer therapy.
[50, 51]. Nevertheless, the precise mechanism underlying
this intercommunication in influencing EP4 expression re-
quired to be determined.
Conclusion
Collectively, our results show that solamargine inhibits
the growth of lung cancer cells through inactivation of
Akt, followed by reduction of SP1 and p65. This results
in the inhibition of expression of EP4 gene. The cross-
talk between SP1 and p65, and the positive feedback
regulatory loop of PI3-K/Akt signaling by EP4 contribute
to the overall responses of solamargine in this process
(Fig. 6e). This study unveils the novel mechanism by
which solamargine inhibits growth of human lung can-
cer cells and reemphasizes the potential target of EP4 in
lung cancer prevention and treatment.
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